Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$1.54M Sell
63,900
-900
-1% -$19K 0.14% 71
2019
Q3
$1.11M Hold
64,800
0.1% 76
2019
Q2
$975K Sell
64,800
-4,200
-6% -$75K 0.09% 81
2019
Q1
$1.39M Sell
69,000
-3,300
-5% -$67K 0.12% 73
2018
Q4
$1.29M Buy
72,300
+300
+0.4% +$5.33K 0.13% 75
2018
Q3
$1.42M Buy
72,000
+39,400
+121% +$812K 0.11% 82
2018
Q2
$645K Sell
32,600
-2,500
-7% -$55K 0.05% 102
2018
Q1
$863K Sell
35,100
-1,300
-4% -$34.2K 0.07% 99
2017
Q4
$1.04M Sell
36,400
-400
-1% -$12.6K 0.08% 94
2017
Q3
$1.01M Buy
36,800
+900
+3% +$19.9K 0.08% 91
2017
Q2
$752K Buy
+35,900
New +$759K 0.06% 95

Other funds holding ACLS

CS McKee's ACLS Position: Q4 2019 in Review

CS McKee reduced its Axcelis (ACLS) stake by 1.4% in Q4 2019, selling an estimated $19K and leaving 63,900 shares worth $1.54M. The position accounts for 0.14% of the portfolio, ranked #71.

CS McKee first reported a position in ACLS in Q2 2017 and has held it in 11 quarters since. 139 funds tracked by Wall St. Rank hold ACLS as of Q4 2019.

  • CS McKee held 63,900 shares of Axcelis worth $1.54M as of Q4 2019.
  • CS McKee sold 900 Axcelis shares in Q4 2019, an estimated $19K.
  • Axcelis made up 0.14% of CS McKee's portfolio in Q4 2019, its #71 holding.
  • CS McKee first reported a position in Axcelis in Q2 2017 and has held it in 11 quarters since.
  • 139 funds tracked by Wall St. Rank held Axcelis as of Q4 2019.

Based on CS McKee's 13F filing for Q4 2019, filed 14 Feb 2020.